# Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

Suelen H. Qassim, MBBS MPH<sup>1,2,3†</sup>, Mohammad R. Hasan, PhD<sup>4†</sup>, Patrick Tang, MD PhD<sup>4†</sup>, Hiam Chemaitelly, PhD<sup>1,2,3</sup>, Houssein H. Ayoub, PhD<sup>5</sup>, Hadi M. Yassine, PhD<sup>6,7</sup>, Hebah A. Al-Khatib, PhD<sup>6,7</sup>, Maria K. Smatti, MSc<sup>6,7</sup>, Hanan F. Abdul-Rahim, PhD<sup>8</sup>, Gheyath K. Nasrallah, PhD<sup>6,7</sup>, Mohamed Ghaith Al-Kuwari, MD<sup>9</sup>, Abdullatif Al-Khal, MD<sup>10</sup>, Peter Coyle, MD<sup>6,10,11</sup>, Imtiaz Gillani MSc<sup>10</sup>, Anvar Hassan Kaleeckal, MSc<sup>10</sup>, Riyazuddin Mohammad Shaik, MSc<sup>10</sup>, Ali Nizar Latif, MD<sup>10</sup>, Einas Al-Kuwari, MD<sup>10</sup>, Andrew Jeremijenko, MD<sup>10</sup>, Adeel A. Butt, MBBS MS<sup>3,10,12</sup>, Roberto Bertollini, MD MPH<sup>13</sup>, Hamad Eid Al-Romaihi, MD<sup>13</sup>, Mohamed H. Al-Thani, MD<sup>13</sup>, and Laith J. Abu-Raddad, PhD<sup>1,2,3,8\*</sup>

†These authors contributed equally.

**Word count:** Abstract: 251 words, Main Text: 1,984 words.

Number of tables: 5. Number of figures: 1.

Running head: Associations with SARS-CoV-2 infectiousness.

**Keywords:** COVID-19; SARS-CoV-2 variant; vaccine; reinfection; breakthrough infection; immunity; epidemiology; PCR.

\*Correspondence to Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health Organization Collaborating Centre for Disease Epidemiology Analytics on

<sup>&</sup>lt;sup>1</sup>Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar

<sup>&</sup>lt;sup>2</sup>World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine—Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

<sup>&</sup>lt;sup>3</sup>Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

<sup>&</sup>lt;sup>4</sup>Department of Pathology, Sidra Medicine, Doha, Qatar

<sup>&</sup>lt;sup>5</sup>Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar

<sup>&</sup>lt;sup>6</sup>Biomedical Research Center, QU Health, Qatar University, Doha, Qatar

<sup>&</sup>lt;sup>7</sup>Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

<sup>&</sup>lt;sup>8</sup>Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

<sup>&</sup>lt;sup>9</sup>Primary Health Care Corporation, Doha, Qatar

<sup>&</sup>lt;sup>10</sup>Hamad Medical Corporation, Doha, Qatar

<sup>&</sup>lt;sup>11</sup>Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom

<sup>&</sup>lt;sup>12</sup>Department of Medicine, Weill Cornell Medicine, Cornell University, New York, USA

<sup>&</sup>lt;sup>13</sup>Ministry of Public Health, Doha, Oatar

HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Qatar Foundation-Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 4492-8321. E-mail: lja2002@qatar-med.cornell.edu.

#### **Abstract**

In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy the inverse of infectiousness, we investigated infectiousness of SARS-CoV-2 infections by variant, age, sex, vaccination status, prior infection status, and reason for testing in a random sample of 18,355 RT-qPCR-genotyped infections. Regression analyses were conducted to estimate associations with the Ct value of RT-qPCR-positive tests. Compared to Beta infections, Alpha and Delta infections demonstrated 2.56 higher Ct cycles (95% CI: 2.35-2.78), and 4.92 fewer cycles (95% CI: 4.67-5.16), respectively. The Ct value declined gradually with age and was especially high for children <10 years of age, signifying lower infectiousness of small children. Children <10 years of age had 2.18 higher Ct cycles (95% CI: 1.88-2.48) than those 10-19 years of age. Compared to unvaccinated individuals, the Ct value was higher among individuals who had received one or two vaccine doses, but the Ct value decreased gradually with time since the second-dose vaccination. Ct value was 2.07 cycles higher (95% CI: 1.42-2.72) for those with a prior infection than those without prior infection. The Ct value was lowest among individuals tested because of symptoms and was highest among individuals tested as a travel requirement. Delta was substantially more infectious than Beta. Prior immunity, whether due to vaccination or prior infection, is associated with lower infectiousness of breakthrough infections, but infectiousness increases gradually with time since the second-dose vaccination.

#### Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues with progressive viral evolution more than two years after it first emerged.(1) Between January 18, 2021 and May 31, 2021, Qatar experienced a SARS-CoV-2 Alpha(2) (B.1.1.7) variant wave(3) that was immediately followed by a Beta(2) (B.1.351) variant wave.(4) Starting in June 2021, the Delta(2) (B.1.617.2) variant dominated a prolonged low-incidence phase that persisted until November of 2021.(5-7) We investigated the effects of SARS-CoV-2 variant, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections.

The real-time (quantitative) reverse transcription-polymerase chain reaction (RT-qPCR) cycle threshold (Ct) value of an RT-qPCR-positive SARS-CoV-2 test is a measure of the inverse of viral load and correlates strongly with culturable virus.(8) Therefore, it can be used to proxy inverse of SARS-CoV-2 infectiousness.(8-13) Higher Ct values signify lower infectiousness.(8-13) We assessed differences in Ct values in a random sample of 18,355 RT-qPCR-genotyped SARS-CoV-2 infections in relation to variant status, age, sex, vaccination status, prior infection status, and reason for testing.

#### Methods

#### Study population, data sources, and study design

This cross sectional study was conducted in the resident population of Qatar, applying a methodology used recently to investigate effects of the BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron(2) (B.1.1.529) infections.(14) Similarly, several effects on the infectiousness of SARS-CoV-2 infections were investigated including pre-Omicron variants (Alpha, Beta, and Delta), mRNA COVID-19 vaccination status

(BNT162b2(15) and mRNA-1273(16)), prior infection status, reason for RT-qPCR testing, study-period month of the RT-qPCR test (to account for the evolving phase of SARS-CoV-2 incidence), and demographic factors, including sex, age, and nationality.

The present study was conducted on a sample of 18,355 SARS-CoV-2 RT-qPCR-positive swabs that were collected randomly on a weekly basis from among all RT-qPCR-confirmed infections in Qatar between March 23, 2021 and November 6, 2021. These documented infections were RT-qPCR genotyped as part of a national project for surveillance of SARS-CoV-2 variants in Qatar.(7, 17-19) Details of laboratory methods for RT-qPCR testing and variant ascertainment are provided in Section 1 of the Supplementary Material. Coronavirus disease 2019 (COVID-19) laboratory testing, vaccination, clinical infection, and demographic data for this population were extracted from the national, federated SARS-CoV-2 databases, which include all RT-qPCR testing, reason for RT-qPCR testing, COVID-19 vaccinations, and related demographic details since the start of the pandemic. Further description of Qatar's national COVID-19 databases has been reported previously.(4, 6, 7, 13, 20)

Every SARS-CoV-2 RT-qPCR test conducted in Qatar is classified based on the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, at port of entry, or other). RT-qPCR testing is performed at a mass scale and most infections are diagnosed not for appearance of symptoms, but because of routine testing.(6) Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥50 years of age, and 89% are expatriates from over 150 countries.(20, 21) Nearly all individuals were vaccinated in Qatar; however, vaccinations performed elsewhere were recorded in the health system at the port of entry upon arrival to Qatar, per national requirements.

For standardization of RT-qPCR Ct values, we analyzed only RT-qPCR-confirmed infections

diagnosed with the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA(22)). For each individual, all RT-qPCR-positive swabs during the study period were included, provided that at least 90 days had elapsed between two consecutive positive swabs to avoid inclusion of positive results from the same infectious episode. (23, 24) A summary measure was derived for the primary outcome, the RT-qPCR Ct value, (25) by averaging Ct values of the N, ORF1ab, and S gene targets. This average Ct value was used as the dependent variable in all analyses. Both vaccination status and prior infection status were ascertained at the time of the RT-qPCR test. Vaccination status was defined by the number of administered vaccine doses and months elapsed since the last vaccine dose, with one month defined as 30 days. Only individuals vaccinated with BNT162b2(15) or mRNA-1273(16) vaccines were included in the analyses, as these have been the vaccines of choice in the COVID-19 immunization program in Qatar.(26-28) Rare occurrences of mixed vaccination regimens were excluded. Nearly all vaccinated persons received their second vaccine dose per protocol(15, 16) within 30 days of first dose. History of prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the study RT-qPCR-positive test.(4, 5, 29, 30) An RT-qPCR-positive test that occurred <90 days prior to the study RT-qPCR-positive test was not considered a prior infection, but was considered a category of its own. This is because the prior RT-qPCR-positive test and the study RT-qPCRpositive test may both reflect the same infection.(23, 24) A small number of RT-qPCR tests that had no recorded Ct value were excluded from the analysis, but these constituted only 0.5% of all RT-qPCR-genotyped infections. Otherwise, data for the remaining study variables were complete.

**Oversight** 

Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The study was reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. The STROBE checklist is found in Supplementary Table 1.

**Statistical analysis** 

Frequency distributions and measures of central tendency were used to describe the study population with respect to a priori determined factors. These included SARS-CoV-2 variant, vaccination status (factoring dose number and months since vaccination), prior infection status, reason for RT-qPCR testing, study-period month of the RT-qPCR test, and demographic factors, age, sex, and nationality.

Association of each of these factors with Ct value was assessed using univariable linear regression analyses. Unadjusted  $\beta$  coefficients, 95% confidence intervals (CIs), and the F-test of overall covariate significance were reported. Adjusted  $\beta$  coefficients and associated 95% CIs and p-values were estimated using multivariable linear regression analyses that included all covariates in the model.

Two-sided p-value <0.05 indicated statistical significance. Interactions were not considered. Statistical analyses were conducted in STATA/SE version 16.(31)

**Results** 

Figure 1 shows the process of selecting the study population and Table 1 describes study population characteristics. This was a national study involving a random sample of 18,355 RT-qPCR-confirmed SARS-CoV-2 infections. Therefore, the study population is broadly

7

representative of the population of Qatar. The sample included 3,347 (18.2%) Alpha infections, 5,576 (30.4%) Beta infections, and 9,432 (51.4%) Delta infections (Table 1).

Compared to Beta infections, Alpha and Delta infections were associated with 2.56 higher Ct cycles (95% CI: 2.35-2.78), and 4.92 fewer cycles (95% CI: 4.67-5.16) (Table 2), respectively, indicating the highest infectiousness for the Delta variant.

Ct value declined gradually with age and was especially high for children <10 years of age, signifying lower infectiousness of small children. Children <10 years of age had 2.18 higher Ct cycles (95% CI: 1.88-2.48) than those 10-19 years of age (Table 2). The 10-19 age group was chosen as a reference, and not the <10 age group, because of the different manifestations of this infection in small children. Males had higher Ct values than females and there were some differences in Ct value by nationality.

Compared to unvaccinated individuals, Ct value was higher among individuals who received one or two vaccine doses (Table 2). However, Ct value decreased gradually with time since second-dose vaccination. Very few individuals received a booster dose during the study period (Table 1) to allow for estimation of effect of booster vaccination on Ct value. Ct value was 2.07 cycles higher (95% CI: 1.42-2.72) for those with a prior infection compared to those without prior infection.

The Ct value was lowest when testing was performed due to suspicion of infection exposure (Table 2), such as appearance of symptoms or recent exposure to an infected person (contact tracing). The Ct value was highest for infections diagnosed because of routine testing for reasons unrelated to infection exposure, such as in a random survey or because of travel requirements. Stratified analyses for Alpha (Table 3), Beta (Table 4), and Delta (Table 5) infections suggested similar findings.

#### **Discussion**

Delta infections were associated with considerably lower Ct values than Beta infections, indicating higher infectiousness of this variant, perhaps because of higher viral load and/or longer duration of infection. This appears to be the first direct comparison of the infectiousness of Delta versus Beta infections, and supports the high infectiousness of the Delta variant compared to pre-Omicron variants such as Alpha, as reported previously. (32, 33) This difference in viral load between Delta and Beta appears also to extend to severity of infection, as Delta infections were found associated with higher severity than Beta infections.(34) Of note that Beta infections were also found earlier to be associated with higher severity than Alpha infections. (35) Prior immunity against SARS-CoV-2 infection, whether due to vaccination or prior infection, was associated with higher Ct value at infection, and thus lower infectiousness of breakthrough infections. This confirms earlier findings, (13, 14) and suggests that strength of immunity is manifest not only in protection against infection, but also against the infectiousness, if a breakthrough infection occurs.(13) However, this effect appeared to depend on the time since the prior immunological event (Table 2). Ct values decreased gradually with time since second-dose vaccination, paralleling the established pattern of waning of vaccine effectiveness after the second dose.(6, 36, 37)

Ct values decreased with age, perhaps reflecting slower virus clearance with aging (38) and confirming our earlier findings.(14) Ct values were particularly high for infections among small children <10 years of age. This finding supports a lesser role for small children than adults in the transmission of infection, as suggested in studies of secondary transmission within households.(39-41) There were differences in Ct value by sex and nationality, but these may be a consequence of different test-seeking behaviors for different socio-economic groups in Qatar's

diverse population. Ct values also varied by reason for testing, with lower Ct values of infections diagnosed because of suspicion of infection, and higher Ct values of infections diagnosed through routine testing unrelated to infection exposure. This finding also confirms our earlier finding for Omicron infections.(14)

The study has limitations. While both Delta and Beta infections had lower Ct values than Alpha infections, this finding should be interpreted with caution. RT-qPCR genotyping in Qatar started only after the Alpha wave peaked in the first week of March 2021. Many Alpha infections may have been older or prolonged infections, rather than recent infections, explaining the higher Ct values of these infections.

Eligible individuals were selected from the pool of those who had documented RT-qPCR-confirmed infections, but other infections may have occurred that were never documented. It is possible that infections in those with prior infections or those vaccinated are less likely to be diagnosed, perhaps because of minimal or no symptoms.(13) Nevertheless, RT-qPCR testing in Qatar is done at a mass scale, where a significant proportion of the population is being tested every week.(6) The majority of infections are identified not because of symptoms, but because of routine testing for other reasons (Table 1).(6) The date of symptom onset was not available for symptomatic cases. Therefore, an analysis factoring the duration between symptom onset and RT-qPCR test was not possible.

A small number of RT-qPCR tests had missing Ct values and were excluded from the analysis, but these constituted only 0.5% of all RT-qPCR-genotyped infections. The study population consisted mostly of working-age adults; thus, the results may not be generalizable to the elderly. Too few individuals received the booster dose during the study period to allow for estimation of effect of booster vaccination on Ct values.

In conclusion, the Delta variant appears substantially more infectious than the Beta variant, explaining its global reach in the pre-Omicron era. Infectiousness of SARS-CoV-2 infections increases with age, apparently reflecting slower virus clearance with aging. Prior immunity against SARS-CoV-2 infection, whether due to vaccination or prior infection, is associated with lower infectiousness of breakthrough infections. However, infectiousness of breakthrough infections increases gradually with time since second-dose vaccination, paralleling the waning of vaccine effectiveness after the second dose.

Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine-Qatar for their diligent efforts and contributions to make this study possible. The authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.

**Author contributions** 

SHQ co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HC co-designed the study and supported the statistical analyses. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

**Competing interests** 

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

12


#### References

- 1. Subissi L, von Gottberg A, Thukral L, Worp N, Oude Munnink BB, Rathore S, et al. An Early Warning System for Emerging Sars-Cov-2 Variants. *Nat Med* (2022). Epub 2022/06/01. doi: 10.1038/s41591-022-01836-w.
- 2. World Health Organization. Tracking Sars-Cov-2 Variants. Available From: Https://Www.Who.Int/En/Activities/Tracking-Sars-Cov-2-Variants/. (2021).
- 3. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Coyle P, Malek JA, Ahmed AA, et al. Introduction and Expansion of the Sars-Cov-2 B.1.1.7 Variant and Reinfections in Qatar: A Nationally Representative Cohort Study. *PLoS Med* (2021) 18(12):e1003879. Epub 2021/12/17. doi: 10.1371/journal.pmed.1003879.
- 4. Chemaitelly H, Bertollini R, Abu-Raddad LJ, National Study Group for Covid Epidemiology. Efficacy of Natural Immunity against Sars-Cov-2 Reinfection with the Beta Variant. *N Engl J Med* (2021) 385(27):2585-6. Epub 2021/12/16. doi: 10.1056/NEJMc2110300.
- 5. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the Omicron Variant from Previous Sars-Cov-2 Infection. *N Engl J Med* (2022). Epub 2022/02/10. doi: 10.1056/NEJMc2200133.
- 6. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of Bnt162b2 Vaccine Protection against Sars-Cov-2 Infection in Qatar. *N Engl J Med* (2021) 385(24):e83. Epub 2021/10/07. doi: 10.1056/NEJMoa2114114.
- 7. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. Bnt162b2 and Mrna-1273 Covid-19 Vaccine Effectiveness against the Sars-Cov-2 Delta Variant in Qatar. *Nat Med* (2021) 27(12):2136-43. Epub 2021/11/04. doi: 10.1038/s41591-021-01583-4.
- 8. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of Infectiousness and Correlation with Rt-Pcr Cycle Threshold Values in Cases of Covid-19, England, January to May 2020. *Euro Surveill* (2020) 25(32). Epub 2020/08/15. doi: 10.2807/1560-7917.ES.2020.25.32.2001483.
- 9. Lyngse FP, Mølbak K, Træholt Franck K, Nielsen C, Skov RL, Voldstedlund M, et al. Association between Sars-Cov-2 Transmissibility, Viral Load, and Age in Households. *medRxiv* (2021):2021.02.28.21252608. doi: 10.1101/2021.02.28.21252608.
- 10. Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. Sars-Cov-2 Infectivity by Viral Load, S Gene Variants and Demographic Factors and the Utility of Lateral Flow Devices to Prevent Transmission. *Clin Infect Dis* (2021). Epub 2021/05/12. doi: 10.1093/cid/ciab421.
- 11. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monne M, et al. Transmission of Covid-19 in 282 Clusters in Catalonia, Spain: A Cohort Study. *Lancet Infect Dis* (2021) 21(5):629-36. Epub 2021/02/06. doi: 10.1016/S1473-3099(20)30985-3.
- 12. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 from Diagnostic Samples. *Clin Infect Dis* (2020) 71(10):2663-6. Epub 2020/05/23. doi: 10.1093/cid/ciaa638.
- 13. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Tang P, Coyle P, Hasan MR, et al. Relative Infectiousness of Sars-Cov-2 Vaccine Breakthrough Infections, Reinfections, and Primary Infections. *Nat Commun* (2022) 13(1):532. Epub 2022/01/29. doi: 10.1038/s41467-022-28199-7.
- 14. Qassim SH, Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et al. Effects of Ba.1/Ba.2 Subvariant, Vaccination, and Prior Infection on Infectiousness of Sars-Cov-2 Omicron Infections. *J Travel Med* (2022). Epub 2022/06/01. doi: 10.1093/jtm/taac068.

- 15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the Bnt162b2 Mrna Covid-19 Vaccine. *N Engl J Med* (2020). doi: 10.1056/NEJMoa2034577.
- 16. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the Mrna-1273 Sars-Cov-2 Vaccine. *N Engl J Med* (2021) 384(5):403-16. Epub 2020/12/31. doi: 10.1056/NEJMoa2035389.
- 17. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar Viral Genome Sequencing Data. Data on Randomly Collected Samples. <a href="https://www.Gisaid.Org/Phylodynamics/Global/Nextstrain/">https://www.Gisaid.Org/Phylodynamics/Global/Nextstrain/</a> (2021). Available from: <a href="https://www.gisaid.org/phylodynamics/global/nextstrain/">https://www.gisaid.org/phylodynamics/global/nextstrain/</a>.
- 18. Benslimane FM, Al Khatib HA, Al-Jamal O, Albatesh D, Boughattas S, Ahmed AA, et al. One Year of Sars-Cov-2: Genomic Characterization of Covid-19 Outbreak in Qatar. *Front Cell Infect Microbiol* (2021) 11:768883. Epub 2021/12/07. doi: 10.3389/fcimb.2021.768883.
- 19. Hasan MR, Kalikiri MKR, Mirza F, Sundararaju S, Sharma A, Xaba T, et al. Real-Time Sars-Cov-2 Genotyping by High-Throughput Multiplex Pcr Reveals the Epidemiology of the Variants of Concern in Qatar. *Int J Infect Dis* (2021) 112:52-4. Epub 2021/09/16. doi: 10.1016/j.ijid.2021.09.006.
- 20. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, et al. Characterizing the Qatar Advanced-Phase Sars-Cov-2 Epidemic. *Sci Rep* (2021) 11(1):6233. Epub 2021/03/20. doi: 10.1038/s41598-021-85428-7.
- 21. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. Available From: <a href="https://www.Psa.Gov.Qa/En/Pages/Default.Aspx">https://www.Psa.Gov.Qa/En/Pages/Default.Aspx</a>. Accessed On: May 26, 2020. (2020).
- 22. Thermo Fisher Scientific. Taqpath<sup>TM</sup> Covid-19 Ce-Ivd Rt-Pcr Kit Instructions for Use. Available From: <a href="https://Assets.Thermofisher.Com/Tfs-Assets/Lsg/Manuals/Man0019215\_Taqpathcovid-19\_Ce-Ivd\_Rt-Pcr%20kit\_Ifu.Pdf">https://Assets.Thermofisher.Com/Tfs-Assets/Lsg/Manuals/Man0019215\_Taqpathcovid-19\_Ce-Ivd\_Rt-Pcr%20kit\_Ifu.Pdf</a>. Accessed
- on December 02, 2020. (2020).
- 23. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of Sars-Cov-2 in an Immunocompromised Host. *N Engl J Med* (2020) 383(23):2291-3. Epub 2020/11/12. doi: 10.1056/NEJMc2031364.
- 24. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, et al. Two Prolonged Viremic Sars-Cov-2 Infections with Conserved Viral Genome for Two Months. *Infect Genet Evol* (2021) 88:104684. Epub 2020/12/23. doi: 10.1016/j.meegid.2020.104684.
- 25. Coyle PV, Al Molawi NH, Kacem M, El Kahlout RA, Al Kuwari E, Al Khal A, et al. Reporting of Rt-Pcr Cycle Threshold (Ct) Values During the First Wave of Covid-19 in Qatar Improved Result Interpretation in Clinical and Public Health Settings. *J Med Microbiol* (2022) 71(5). Epub 2022/05/17. doi: 10.1099/jmm.0.001499.
- 26. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid Vaccination. Effectiveness of the Bnt162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* (2021) 385(2):187-9. Epub 2021/05/06. doi: 10.1056/NEJMc2104974.
- 27. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. Mrna-1273 Covid-19 Vaccine Effectiveness against the B.1.1.7 and B.1.351 Variants and Severe Covid-19 Disease in Qatar. *Nat Med* (2021) 27(9):1614-21. Epub 2021/07/11. doi: 10.1038/s41591-021-01446-y.
- 28. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, et al. Association of Prior Sars-Cov-2 Infection with Risk of Breakthrough Infection

- Following Mrna Vaccination in Qatar. *JAMA* (2021) 326(19):1930-9. Epub 2021/11/02. doi: 10.1001/jama.2021.19623.
- 29. Kojima N, Shrestha NK, Klausner JD. A Systematic Review of the Protective Effect of Prior Sars-Cov-2 Infection on Repeat Infection. *Eval Health Prof* (2021) 44(4):327-32. Epub 2021/10/02. doi: 10.1177/01632787211047932.
- 30. Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. Sars-Cov-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. *Environ Res* (2022):112911. Epub 2022/02/13. doi: 10.1016/j.envres.2022.112911.
- 31. StataCorp. Statistical Software: Release 16.1. *College Station, TX: Stata Corporation* (2019).
- 32. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston DC, Li M, et al. Infection with the Sars-Cov-2 Delta Variant Is Associated with Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. *Clinical Infectious Diseases* (2021):ciab986. doi: 10.1093/cid/ciab986.
- 33. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, Viral Kinetics and Clinical Characteristics of the Emergent Sars-Cov-2 Delta Voc in Guangzhou, China. *EClinicalMedicine* (2021) 40. doi: 10.1016/j.eclinm.2021.101129.
- 34. Butt AA, Dargham SR, Chemaitelly H, Al Khal A, Tang P, Hasan MR, et al. Severity of Illness in Persons Infected with the Sars-Cov-2 Delta Variant Vs Beta Variant in Qatar. *JAMA Intern Med* (2022) 182(2):197-205. Epub 2021/12/23. doi: 10.1001/jamainternmed.2021.7949.
- 35. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, et al. Severity, Criticality, and Fatality of the Sars-Cov-2 Beta Variant. *Clin Infect Dis* (2021):2021.08.02.21261465. Epub 2021/10/18. doi: 10.1093/cid/ciab909.
- 36. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of Effectiveness of Vaccines against Sars-Cov-2 Infection and Covid-19 Disease: Results of a Systematic Review and Meta-Regression. *Lancet* (2022) 399(10328):924-44. Epub 2022/02/25. doi: 10.1016/S0140-6736(22)00152-0.
- 37. Abu-Raddad LJ, Chemaitelly H, Bertollini R, National Study Group for Covid Vaccination. Waning Mrna-1273 Vaccine Effectiveness against Sars-Cov-2 Infection in Qatar. *N Engl J Med* (2022). Epub 2022/01/27. doi: 10.1056/NEJMc2119432.
- 38. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of Protection against Reinfection with Sars-Cov-2 among 4 Million Pcr-Tested Individuals in Denmark in 2020: A Population-Level Observational Study. *Lancet* (2021) 397(10280):1204-12. Epub 2021/03/21. doi: 10.1016/S0140-6736(21)00575-4.
- 39. Zhu Y, Bloxham CJ, Hulme KD, Sinclair JE, Tong ZWM, Steele LE, et al. A Meta-Analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. *Clin Infect Dis* (2021) 72(12):e1146-e53. Epub 2020/12/08. doi: 10.1093/cid/ciaa1825.
- 40. Davies NG, Klepac P, Liu Y, Prem K, Jit M, group CC-w, et al. Age-Dependent Effects in the Transmission and Control of Covid-19 Epidemics. *Nat Med* (2020). doi: 10.1038/s41591-020-0962-9.
- 41. Hasan MR, Ahmad MN, Dargham SR, Zayed H, Al Hashemi A, Ngwabi N, et al. Nasopharyngeal Expression of Angiotensin-Converting Enzyme 2 and Transmembrane Serine Protease 2 in Children within Sars-Cov-2-Infected Family Clusters. *Microbiol Spectr* (2021) 9(3):e0078321. Epub 2021/11/04. doi: 10.1128/Spectrum.00783-21.

Figure 1. Flowchart describing the population selection process for investigating infectiousness of SARS-CoV-2 Alpha, Beta and Delta infections.



Abbreviations: COVID-19, coronavirus disease 2019; RT-qPCR, real-time reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

**Table 1.** Characteristics of the 18,355 RT-qPCR-genotyped SARS-CoV-2 infections between March 23 and November 6, 2021.

Characteristics	Total sample N (%)	Alpha infections N (%)	Beta infections N (%)	Delta infections N (%)
Total N	18,355	3,347 (18.2)	5,576 (30.4)	9,432 (51.4)
Demographic characteristics				
Median age (IQR) — years	32 (22-41)	33 (25-41)	33 (25-42)	31 (18-40)
Age group in years — no. (%)		,	,	- ()
<10	1,956 (10.7)	286 (8.5)	424 (7.6)	1,246 (13.2)
10-19	2,042 (11.1)	277 (8.3)	499 (8.9)	1,266 (13.4)
20-29	3,670 (20.0)	749 (22.4)	1,104 (19.8)	1,817 (19.3)
30-39	5,624 (30.6)	1,104 (33.0)	1,866 (33.5)	2,654 (28.1)
40-49	3,263 (17.8)	627 (18.7)	1,074 (19.3)	1,562 (16.6)
50-59	1,240 (6.8)	210 (6.3)	431 (7.7)	599 (6.4)
60-69	426 (2.3)	73 (2.2)	134 (2.4)	219 (2.3)
70-79	95 (0.5)	14 (0.4)	31 (0.6)	50 (0.5)
80+	39 (0.2)	7 (0.2)	13 (0.2)	19 (0.2)
Sex				
Female	6,805 (37.1)	1,114 (33.3)	1,813 (32.5)	3,878 (41.1)
Male	11,550 (62.9)	2,233 (66.7)	3,763 (67.5)	5,554 (58.9)
Nationality <sup>†</sup>				
Bangladeshi	1,077 (5.9)	240 (7.2)	470 (8.4)	367 (3.9)
Egyptian	1,098 (6.0)	115 (3.4)	311 (5.6)	672 (7.1)
Filipino	1,555 (8.5)	340 (10.2)	582 (10.4)	633 (6.7)
Indian	3,873 (21.1)	855 (25.5)	1,355 (24.3)	1,663 (17.6)
Nepalese	1,084 (5.9)	225 (6.7)	459 (8.2)	400 (4.2)
Pakistani	1,017 (5.5)	223 (6.7)	279 (5.0)	515 (5.5)
Qatari	3,903 (21.3)	555 (16.6)	850 (15.2)	2,498 (26.5)
Sri Lankan	488 (2.7)	106 (3.2)	216 (3.9)	166 (1.8)
Sudanese	394 (2.1)	92 (2.7)	108 (1.9)	194 (2.1)
Other nationalities:	3,866 (21.1)	596 (17.8)	946 (17.0)	2,324 (24.6)
RT-qPCR test characteristics				
Reason for RT-qPCR testing	< 400 ( <b>27</b> 4)	1.045 (01.0)	0.455 (4.4.4)	2.055 (21.2)
Clinical suspicion	6,499 (35.4)	1,067 (31.9)	2,477 (44.4)	2,955 (31.3)
Contact tracing	2,261 (12.3)	404 (12.1)	775 (13.9)	1,082 (11.5)
Healthcare routine testing	532 (2.9)	115 (3.4)	218 (3.9)	199 (2.1)
Survey	2,770 (15.1)	552 (16.5)	938 (16.8)	1,280 (13.6)
Port of entry	3,245 (17.7)	522 (15.6)	291 (5.2)	2,432 (25.8)
Pre-travel	1,243 (6.8)	201 (6.0)	225 (4.0)	817 (8.7)
Individual request Other	1,620 (8.8)	435 (13.0)	603 (10.8)	582 (6.2)
RT-qPCR test study-period month	185 (1.0)	51 (1.5)	49 (0.9)	85 (0.9)
23 March-21 April, 2021	5,185 (28.2)	1,415 (42.3)	3,564 (63.9)	206 (2.2)
22 April-21 May, 2021	2,502 (13.6)	736 (22.0)	1,262 (22.6)	504 (5.3)
22 May-20 June, 2021	1,287 (7.0)	597 (17.8)	226 (4.1)	464 (4.9)
21 June-20 July, 2021	1,263 (6.9)	258 (7.7)	111 (2.0)	894 (9.5)
21 July-19 August, 2021	3,647 (19.9)	253 (7.6)	326 (5.8)	3,068 (32.5)
20 August-18 September, 2021	2,807 (15.3)	88 (2.6)	87 (1.6)	2,632 (27.9)
19 September-18 October, 2021	976 (5.3)	0 (0.0)	0 (0.0)	976 (10.3)
19 October-06 November, 2021	688 (3.7)	0 (0.0)	0 (0.0)	688 (7.3)
Vaccine and natural immunity	000 (3.7)	0 (0.0)	0 (0.0)	000 (7.3)
Vaccination status				
Unvaccinated	12,865 (70.1)	2,760 (82.5)	4,429 (79.4)	5,676 (60.2)
One dose	1,053 (5.7)	239 (7.1)	582 (10.4)	232 (2.5)
Two doses	1,000 (0.1)	23) (1.1)	JUZ (10. <del>4</del> )	232 (2.3)
<3 months before the RT-qPCR test	1,388 (7.6)	258 (7.7)	449 (8.1)	681 (7.2)
3-<6 months before the RT-qPCR test	2,469 (13.5)	86 (2.6)	107 (1.9)	2,276 (24.1)
	4,TU/(13.J)	00 (2.0)	10/(1.7)	2,210 (27.1)
6-<9 months before the RT-qPCR test	567 (3.1)	3 (0.1)	7 (0.1)	557 (5.9)

Three doses				
≤1 month before the RT-qPCR test	5 (0.0)	1 (0.0)	2 (0.0)	2 (0.0)
>1 month before the RT-qPCR test	4 (0.0)	0 (0.0)	0(0.0)	4 (0.0)
Prior SARS-CoV-2 infection				
Never	15,785 (86.0)	2,540 (75.9)	4,911 (88.1)	8,334 (88.4)
<90 days before the study RT-qPCR test§	2,362 (12.9)	772 (23.1)	605 (10.9)	985 (10.4)
Prior infection <sup>¶</sup>	208 (1.1)	35 (1.0)	60 (1.1)	113 (1.2)

Abbreviations: IQR, interquartile range; RT-qPCR, real-time reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>\*</sup>Nationalities were chosen to represent the most populous groups in Qatar.

\*These comprise 99 other nationalities in Qatar.

\*An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included as a separate category in the analysis and was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection.

\*Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study.

**Table 2.** Associations with RT-qPCR Ct value among the 18,355 RT-qPCR-genotyped SARS-CoV-2 infections between March 23 and November 6, 2021.

Characteristics	RT-qPCR Ct value	Univariable analysis		F-test*	Multivariable analysis†	
	Mean (SD)	β coefficient [95% CI]	p-value	p-value	β coefficient [95% CI]	p-value
Age group in years				< 0.001		
10-19‡	23.23 (5.39)	Ref.			Ref.	
<10	25.51 (5.06)	2.28 [1.93, 2.63]	< 0.001		2.18 [1.88, 2.48]	< 0.001
20-29	23.74 (5.80)	0.52 [0.21, 0.82]	0.001		-0.24 [-0.51, 0.04]	0.091
30-39	23.63 (5.73)	0.41 [0.12, 0.69]	0.005		-0.39 [-0.65, -0.12]	0.004
40-49	23.43 (5.78)	0.20 [-0.11, 0.51]	0.204		-0.52 [-0.81, -0.23]	< 0.001
50-59	23.55 (5.50)	0.33 [-0.07, 0.72]	0.106		-0.44 [-0.80, -0.09]	0.014
60-69	23.35 (5.31)	0.12 [-0.46, 0.71]	0.677		-0.55 [-1.06, -0.04]	0.036
70-79	22.70 (5.23)	-0.52 [-1.68, 0.63]	0.375		-1.01 [-1.99, -0.03]	0.044
80+	22.86 (5.27)	-0.37 [-2.15, 1.42]	0.688		-0.83 [-2.33, 0.68]	0.280
Sex	, ,	, ,		< 0.001	. , ,	
Female	23.05 (5.48)	Ref.			Ref.	
Male	24.17 (5.72)	1.13 [0.96, 1.29]	< 0.001		0.60 [0.45, 0.76]	< 0.001
Nationality§	, ,	[,]		< 0.001		
Qatari	23.13 (5.31)	Ref.			Ref.	
Bangladeshi	24.34 (5.94)	1.20 [0.82, 1.58]	< 0.001		0.55 [0.20, 0.90]	0.002
Egyptian	23.53 (5.38)	0.40 [0.02, 0.77]	0.039		0.23 [-0.09, 0.56]	0.161
Filipino	23.25 (5.72)	0.11 [-0.22, 0.45]	0.496		0.19 [-0.12, 0.49]	0.227
Indian	24.40 (5.96)	1.27 [1.02, 1.52]	< 0.001		0.65 [0.41, 0.90]	< 0.001
Nepalese	24.31 (5.80)	1.18 [0.80, 1.56]	< 0.001		0.85 [0.49, 1.20]	< 0.001
Pakistani	24.23 (5.69)	1.09 [0.71, 1.48]	< 0.001		0.24 [-0.10, 0.59]	0.170
Sri Lankan	24.18 (5.70)	1.05 [0.52, 1.58]	< 0.001		0.29 [-0.17, 0.75]	0.217
Sudanese	23.79 (5.06)	0.66 [0.07, 1.24]	0.027		0.64 [0.14, 1.14]	0.012
Other nationalities <sup>¶</sup>	23.51 (5.55)	0.38 [0.13, 0.63]	0.003		0.29 [0.07, 0.50]	0.011
SARS-CoV-2 variant		[,]		< 0.001	[,]	
Beta**	23.72 (5.14)	Ref.			Ref.	
Alpha	27.89 (5.65)	4.17 [3.94, 4.39]	< 0.001		2.56 [2.35, 2.78]	< 0.001
Delta	22.31 (5.21)	-1.41 [-1.59, -1.24]	< 0.001		-4.92 [-5.16, -4.67]	< 0.001
Reason for RT-qPCR testing	22.61 (6.21)	1[ 1.62, 1.2.]	10.001	< 0.001	, 2 [ 2.12,,	10.001
Survey	24.23 (5.52)	Ref.		(0.001	Ref.	
Clinical suspicion	22.64 (5.42)	-1.59 [-1.84, -1.34]	< 0.001		-1.48 [-1.69, -1.26]	< 0.001
Contact tracing	23.52 (5.52)	-0.71 [-1.02, -0.40]	< 0.001		-0.53 [-0.80, -0.26]	< 0.001
Healthcare routine testing	24.20 (5.65)	-0.03 [-0.55, 0.49]	0.913		-0.72 [-1.17, -0.28]	0.001
Port of entry	24.24 (5.66)	0.01 [-0.27, 0.29]	0.934		0.84 [0.59, 1.09]	< 0.001
Pre-travel	25.66 (5.66)	1.43 [1.06, 1.81]	< 0.001		1.29 [0.97, 1.62]	< 0.001
Individual request	24.89 (6.03)	0.66 [0.32, 1.00]	< 0.001		0.24 [-0.07, 0.54]	0.125
Other	26.11 (5.62)	1.88 [1.05, 2.71]	< 0.001		-1.01 [-1.73, -0.29]	0.006
RT-qPCR test study-period month	20.11 (J.U2)	1.00 [1.03, 2.71]	\0.001	< 0.001	-1.01 [-1.73, -0.27]	0.000
23 March-21 April, 2021	23.39 (5.15)	Ref.		<0.001	Ref.	
25 March-21 April, 2021	23.39 (3.13)	IXCI.			NCI.	

22 April-21 May, 2021	24.20 (5.45)	0.82 [0.55, 1.08]	< 0.001		1.00 [0.77, 1.23]	< 0.001
22 May-20 June, 2021	27.50 (6.46)	4.12 [3.78, 4.46]	< 0.001		4.08 [3.76, 4.39]	< 0.001
21 June-20 July, 2021	23.07 (5.97)	-0.32 [-0.66, 0.02]	0.068		2.57 [2.23, 2.91]	< 0.001
21 July-19 August, 2021	23.29 (5.77)	-0.09 [-0.33, 0.14]	0.442		3.80 [3.52, 4.09]	< 0.001
20 August-18 September, 2021	23.96 (5.62)	0.58 [0.32, 0.83]	< 0.001		4.97 [4.66, 5.29]	< 0.001
19 September-18 October, 2021	23.04 (5.20)	-0.35 [-0.72, 0.03]	0.074		4.46 [4.05, 4.87]	< 0.001
19 October-06 November, 2021	21.76 (4.85)	-1.62 [-2.06, -1.18]	< 0.001		3.66 [3.20, 4.12]	< 0.001
Vaccination status				< 0.001		
Unvaccinated	23.98 (5.65)	Ref.			Ref.	
One dose	23.93 (5.71)	-0.05 [-0.40, 0.31]	0.790		0.57 [0.26, 0.87]	< 0.001
Two doses						
<3 months before the RT-qPCR test	24.43 (5.86)	0.45 [0.14, 0.77]	0.004		0.86 [0.59, 1.13]	< 0.001
3-<6 months before the RT-qPCR test	22.59 (5.40)	-1.39 [-1.63, -1.15]	< 0.001		0.08 [-0.17, 0.32]	0.547
6-<9 months before the RT-qPCR test	21.79 (5.12)	-2.19 [-2.66, -1.71]	< 0.001		-0.26 [-0.72, 0.19]	0.262
≥9 months before the RT-qPCR test	18.81 (2.22)	-5.17 [-10.68, 0.34]	0.066		-3.23 [-7.89, 1.42]	0.173
Three doses						
≤1 month before the RT-qPCR test	22.99 (5.40)	-0.99 [-5.92, 3.94]	0.693		-1.36 [-5.52, 2.79]	0.520
>1 month before the RT-qPCR test	19.80 (2.97)	-4.18 [-9.69, 1.33]	0.137		-1.83 [-6.47, 2.81]	0.439
Prior SARS-CoV-2 infection				< 0.001		
Never	23.14 (5.51)	Ref.			Ref.	
<90 days before the study RT-qPCR test <sup>††</sup>	27.65 (4.93)	4.51 [4.27, 4.74]	< 0.001		3.95 [3.73, 4.17]	< 0.001
Prior infection <sup>‡‡</sup>	25.88 (5.93)	2.74 [1.99, 3.48]	< 0.001		2.07 [1.42, 2.72]	< 0.001

Abbreviations: CI, confidence interval; Ct, cycle threshold; RT-qPCR, real-time reverse-transcription polymerase chain reaction; Ref., reference; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.

<sup>\*</sup>The two-tailed F-test of the univariable analysis.

<sup>†</sup>RT-qPCR Ct value was adjusted for age-group, sex, nationality, SARS-CoV-2 variant, reason for RT-qPCR test, RT-qPCR test study-period month, vaccination status, and prior SARS-CoV-2 infection.

The 10-19 age group was chosen as a reference, and not the <10 age group, because of the different manifestations of this infection in small children.

<sup>§</sup>Nationalities were chosen to represent the most populous groups on Qatar.

These comprise 99 other nationalities in Qatar.

<sup>\*\*</sup>Beta was chosen as a reference because of interest in directly comparing Delta to Beta infections.

<sup>&</sup>lt;sup>††</sup>An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included as a separate category in the analysis and was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection.

<sup>\*\*</sup>Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study.

**Table 3.** Associations with RT-qPCR Ct value among 3,347 Alpha RT-qPCR-genotyped SARS-CoV-2 infections between March 23 and November 6, 2021.

Characteristics	RT-qPCR Ct value	Univariable analysis		F-test*	Multivariable analysis†	
	Mean (SD)	β coefficient [95% CI]	p-value	p-value	β coefficient [95% CI]	p-value
Age group in years				< 0.001		
10-19‡	26.24 (5.93)	Ref.			Ref.	
<10	27.60 (5.17)	1.36 [0.43, 2.29]	0.004		1.28 [0.50, 2.06]	0.001
20-29	28.48 (5.50)	2.24 [1.46, 3.01]	< 0.001		0.20 [-0.49, 0.88]	0.577
30-39	28.12 (5.72)	1.88 [1.14, 2.62]	< 0.001		0.04 [-0.63, 0.71]	0.910
40-49	27.81 (5.78)	1.57 [0.78, 2.37]	< 0.001		-0.16 [-0.87, 0.55]	0.661
50-59	27.94 (5.32)	1.70 [0.69, 2.71]	0.001		-0.18 [-1.07, 0.71]	0.694
60-69	27.07 (5.33)	0.83 [-0.62, 2.28]	0.263		-1.14 [-2.38, 0.10]	0.072
70-79	24.88 (6.01)	-1.36 [-4.38, 1.66]	0.377		-2.70 [-5.23, -0.17]	0.037
80+	25.93 (3.81)	-0.30 [-4.52, 3.91]	0.887		-0.13 [-3.65, 3.40]	0.943
Sex				< 0.001		
Female	26.24 (5.81)	Ref.			Ref.	
Male	28.71 (5.38)	2.47 [2.07, 2.86]	< 0.001		0.74 [0.35, 1.13]	< 0.001
Nationality§	, ,	, ,		< 0.001	2 , 1	
Qatari	26.21 (5.58)	Ref.			Ref.	
Bangladeshi	29.34 (5.07)	3.13 [2.30, 3.96]	< 0.001		1.77 [0.98, 2.56]	< 0.001
Egyptian	26.45 (6.07)	0.24 [-0.87, 1.34]	0.674		0.39 [-0.57, 1.35]	0.429
Filipino	26.57 (5.76)	0.36 [-0.38, 1.10]	0.339		0.84 [0.14, 1.53]	0.019
Indian	29.57 (5.23)	3.36 [2.78, 3.95]	< 0.001		1.95 [1.36, 2.55]	< 0.001
Nepalese	29.44 (5.15)	3.23 [2.38, 4.08]	< 0.001		2.32 [1.51, 3.12]	< 0.001
Pakistani	28.08 (5.24)	1.87 [1.02, 2.72]	< 0.001		0.70 [-0.09, 1.50]	0.083
Sri Lankan	27.74 (6.08)	1.53 [0.39, 2.67]	0.009		0.72 [-0.31, 1.74]	0.170
Sudanese	26.50 (5.11)	0.29 [-0.92, 1.50]	0.635		0.90 [-0.16, 1.96]	0.097
Other nationalities <sup>¶</sup>	27.06 (5.77)	0.85 [0.22, 1.48]	0.009		0.66 [0.09, 1.23]	0.023
Reason for RT-qPCR testing	,	, ,		< 0.001	, ,	
Survey	28.26 (5.43)	Ref.			Ref.	
Clinical suspicion	26.39 (5.87)	-1.87 [-2.43, -1.30]	< 0.001		-1.54 [-2.04, -1.04]	< 0.001
Contact tracing	27.05 (5.87)	-1.21 [-1.92, -0.50]	0.001		-0.54 [-1.15, 0.08]	0.088
Healthcare routine testing	28.20 (5.77)	-0.06 [-1.17, 1.05]	0.915		-0.42 [-1.38, 0.53]	0.387
Port of entry	28.61 (5.07)	0.35 [-0.30, 1.01]	0.291		-0.17 [-0.76, 0.42]	0.568
Pre-travel	30.58 (4.45)	2.32 [1.43, 3.21]	< 0.001		0.01 [-0.77, 0.80]	0.976
Individual request	29.58 (5.18)	1.33 [0.64, 2.02]	< 0.001		0.38 [-0.23, 0.99]	0.221
Other	28.81 (5.13)	0.56 [-1.02, 2.13]	0.490		-1.42 [-2.80, -0.05]	0.042
RT-qPCR test study-period month	(11.17)			< 0.001	. [,]	
23 March-21 April, 2021	25.15 (5.76)	Ref.			Ref.	
22 April-21 May, 2021	27.82 (5.20)	2.67 [2.23, 3.11]	< 0.001		1.95 [1.53, 2.38]	< 0.001
22 May-20 June, 2021	31.55 (4.25)	6.40 [5.92, 6.87]	< 0.001		4.92 [4.43, 5.41]	< 0.001
21 June-20 July, 2021	30.10 (3.24)	4.95 [4.29, 5.61]	< 0.001		3.75 [3.09, 4.40]	< 0.001
21 July-19 August, 2021	30.94 (2.92)	5.79 [5.12, 6.46]	< 0.001		4.52 [3.84, 5.21]	< 0.001

20 August-18 September, 2021	32.41 (2.03)	7.26 [6.19, 8.33]	< 0.001	6.06 [5.00, 7.12]	< 0.001
19 September-18 October, 2021	_**	_**		-**	
19 October-06 November, 2021	_**	_**		_**	
Vaccination status			< 0.001		
Unvaccinated	27.52 (5.71)	Ref.		Ref.	
One dose	28.32 (5.56)	0.80 [0.06, 1.54]	0.034	1.37 [0.73, 2.00]	< 0.001
Two doses					
<3 months before the RT-qPCR test	30.47 (4.63)	2.95 [2.24, 3.67]	< 0.001	1.54 [0.91, 2.18]	< 0.001
3-<6 months before the RT-qPCR test	30.61 (3.40)	3.10 [1.90, 4.29]	< 0.001	1.14 [0.04, 2.25]	0.042
6-<9 months before the RT-qPCR test	33.89 (2.36)	6.38 [0.06, 12.69]	0.048	5.10 [-0.32, 10.52]	0.065
≥9 months before the RT-qPCR test	-**	_**		**	
Three doses					
≤1 month before the RT-qPCR test	29.24 (-)	1.73 [-9.21, 12.66]	0.757	-4.05 [-13.26, 5.15]	0.388
>1 month before the RT-qPCR test	**	**		**	
Prior SARS-CoV-2 infection			< 0.001		
Never	27.04 (5.88)	Ref.		Ref.	
<90 days before the study RT-qPCR test <sup>††</sup>	30.50 (3.79)	3.46 [3.02, 3.90]	< 0.001	3.07 [2.66, 3.49]	< 0.001
Prior infection#	32.05 (3.14)	5.01 [3.19, 6.83]	< 0.001	1.83 [0.24, 3.42]	0.024

Abbreviations: CI, confidence interval; Ct, cycle threshold; RT-qPCR, real-time reverse-transcription polymerase chain reaction; Ref., reference; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.

<sup>\*</sup>The two-tailed F-test of the univariable analysis.

<sup>†</sup>RT-qPCR Ct value was adjusted for age-group, sex, nationality, reason for RT-qPCR test, RT-qPCR test study-period month, vaccination status, and prior SARS-CoV-2 infection. †The 10-19 age group was chosen as a reference, and not the <10 age group, because of the different manifestations of this infection in small children.

<sup>§</sup>Nationalities were chosen to represent the most populous groups on Qatar.

These comprise 63 other nationalities in Qatar.

<sup>\*\*</sup>Inestimable quantity due to very small number of observations.

<sup>†</sup>An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included as a separate category in the analysis and was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection.

<sup>\*\*</sup>Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study.

**Table 4.** Associations with RT-qPCR Ct value among 5,576 Beta RT-qPCR-genotyped SARS-CoV-2 infections between March 23 and November 6, 2021.

Characteristics	RT-qPCR Ct value	Univariable analysis		F-test*	Multivariable analysis†	
	Mean (SD)	β coefficient [95% CI]	p-value	p-value	β coefficient [95% CI]	p-value
Age group in years				< 0.001		
10-19‡	23.53 (5.25)	Ref.			Ref.	
<10	25.91 (5.02)	2.38 [1.72, 3.04]	< 0.001		1.80 [1.22, 2.38]	< 0.001
20-29	23.56 (5.24)	0.04 [-0.50, 0.58]	0.892		-0.00 [-0.50, 0.49]	0.991
30-39	23.40 (5.09)	-0.13 [-0.63, 0.38]	0.623		-0.10 [-0.58, 0.37]	0.666
40-49	23.63 (5.05)	0.10 [-0.44, 0.65]	0.705		0.18 [-0.33, 0.69]	0.495
50-59	23.93 (5.01)	0.40 [-0.26, 1.06]	0.235		0.18 [-0.42, 0.79]	0.549
60-69	23.52 (4.29)	-0.01 [-0.98, 0.97]	0.988		-0.21 [-1.08, 0.66]	0.629
70-79	22.59 (5.51)	-0.93 [-2.78, 0.92]	0.323		-1.21 [-2.83, 0.41]	0.143
80+	23.36 (5.43)	-0.17 [-2.98, 2.64]	0.904		-1.26 [-3.71, 1.19]	0.314
Sex				0.020		
Female	23.49 (5.15)	Ref.			Ref.	
Male	23.83 (5.13)	0.34 [0.05, 0.63]	0.020		0.32 [0.04, 0.60]	0.023
Nationality§	, ,	2		0.132	, ,	
Qatari	23.88 (5.28)	Ref.			Ref.	
Bangladeshi	23.80 (4.98)	-0.08 [-0.66, 0.50]	0.790		0.64 [0.09, 1.19]	0.023
Egyptian	23.86 (5.08)	-0.02 [-0.69, 0.65]	0.950		0.67 [0.08, 1.26]	0.026
Filipino	23.42 (5.02)	-0.46 [-1.00, 0.08]	0.098		0.68 [0.18, 1.19]	0.008
Indian	23.81 (5.20)	-0.07 [-0.51, 0.38]	0.771		0.62 [0.19, 1.05]	0.005
Nepalese	23.37 (5.15)	-0.50 [-1.09, 0.08]	0.090		0.53 [-0.03, 1.09]	0.064
Pakistani	24.34 (5.21)	0.46 [-0.24, 1.15]	0.197		0.45 [-0.18, 1.07]	0.159
Sri Lankan	23.17 (4.90)	-0.71 [-1.47, 0.06]	0.071		0.22 [-0.48, 0.92]	0.540
Sudanese	23.09 (4.61)	-0.79 [-1.82, 0.24]	0.133		0.39 [-0.51, 1.29]	0.401
Other nationalities <sup>¶</sup>	23.72 (5.16)	-0.16 [-0.64, 0.31]	0.506		0.43 [0.00, 0.86]	0.048
Reason for RT-qPCR testing	,	, ,		< 0.001	, ,	
Survey	24.30 (4.85)	Ref.			Ref.	
Clinical suspicion	22.78 (4.89)	-1.52 [-1.89, -1.14]	< 0.001		-1.47 [-1.81, -1.14]	< 0.001
Contact tracing	23.46 (5.03)	-0.84 [-1.31, -0.36]	0.001		-0.68 [-1.11, -0.25]	0.002
Healthcare routine testing	23.45 (4.93)	-0.85 [-1.59, -0.12]	0.023		-1.44 [-2.10, -0.78]	< 0.001
Port of entry	27.24 (5.46)	2.94 [2.29, 3.60]	< 0.001		0.35 [-0.27, 0.97]	0.268
Pre-travel	26.82 (5.25)	2.52 [1.79, 3.24]	< 0.001		0.55 [-0.12, 1.22]	0.108
Individual request	24.14 (5.15)	-0.16 [-0.67, 0.35]	0.549		-0.25 [-0.71, 0.21]	0.293
Other	24.86 (6.00)	0.56 [-0.87, 2.00]	0.442		-2.19 [-3.48, -0.91]	0.001
RT-qPCR test study-period month	,	Ly		< 0.001	- L - · · · · J	
23 March-21 April, 2021	22.79 (4.73)	Ref.			Ref.	
22 April-21 May, 2021	23.16 (4.70)	0.37 [0.07, 0.67]	0.016		0.15 [-0.13, 0.44]	0.297
22 May-20 June, 2021	26.81 (5.64)	4.02 [3.40, 4.65]	< 0.001		3.13 [2.53, 3.74]	< 0.001
21 June-20 July, 2021	28.73 (3.86)	5.94 [5.06, 6.81]	< 0.001		4.65 [3.80, 5.50]	< 0.001

21 July-19 August, 2021	30.48 (2.85)	7.69 [7.16, 8.21]	< 0.001	6.41 [5.82, 7.00]	< 0.001
20 August-18 September, 2021	30.13 (3.66)	7.34 [6.36, 8.33]	< 0.001	6.07 [5.09, 7.05]	< 0.001
19 September-18 October, 2021	_**	**		** -	
19 October-06 November, 2021	_**	**		** -	
Vaccination status				< 0.001	
Unvaccinated	23.59 (5.08)	Ref.		Ref.	
One dose	23.21 (4.91)	-0.38 [-0.82, 0.06]	0.091	0.34 [-0.05, 0.73]	0.087
Two doses					
<3 months before the RT-qPCR test	24.26 (5.31)	0.67 [0.18, 1.16]	0.008	0.68 [0.23, 1.13]	0.003
3-<6 months before the RT-qPCR test	29.16 (4.58)	5.57 [4.60, 6.54]	< 0.001	0.48 [-0.47, 1.43]	0.325
6-<9 months before the RT-qPCR test	30.28 (4.50)	6.69 [2.93, 10.45]	< 0.001	0.06 [-3.28, 3.40]	0.973
≥9 months before the RT-qPCR test	**	**		**	
Three doses					
≤1 month before the RT-qPCR test	25.13 (2.72)	1.54 [-5.49, 8.57]	0.668	2.39 [-3.76, 8.53]	0.446
>1 month before the RT-qPCR test	_**	**		**	
Prior SARS-CoV-2 infection				< 0.001	
Never	23.19 (5.01)	Ref.		Ref.	
<90 days before the study RT-qPCR test <sup>††</sup>	27.82 (4.17)	4.63 [4.21, 5.04]	< 0.001	4.14 [3.75, 4.53]	< 0.001
Prior infection#	25.83 (5.31)	2.64 [1.38, 3.89]	< 0.001	2.04 [0.91, 3.17]	< 0.001

Abbreviations: CI, confidence interval; Ct, cycle threshold; RT-qPCR, real-time reverse-transcription polymerase chain reaction; Ref., reference; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.

<sup>\*</sup>The two-tailed F-test of the univariable analysis.

<sup>†</sup>RT-qPCR Ct value was adjusted for age-group, sex, nationality, reason for RT-qPCR test, RT-qPCR test study-period month, vaccination status, and prior SARS-CoV-2 infection.

The 10-19 age group was chosen as a reference, and not the <10 age group, because of the different manifestations of this infection in small children.

<sup>§</sup>Nationalities were chosen to represent the most populous groups on Qatar.

These comprise 60 other nationalities in Qatar.

<sup>\*\*</sup>Inestimable quantity due to very small number of observations.

<sup>&</sup>lt;sup>††</sup>An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included separately in the analysis, but was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection.

Frior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study.

**Table 5.** Associations with RT-qPCR Ct value among 9,432 Delta RT-qPCR-genotyped SARS-CoV-2 infections between March 23 and November 6, 2021.

Characteristics	RT-qPCR Ct value	Univariable analysis		F-test*	Multivariable analysis†	
	Mean (SD)	β coefficient [95% CI]	p-value	p-value	β coefficient [95% CI]	p-value
Age group in years				< 0.001		
10-19‡	22.45 (5.07)	Ref.			Ref.	
<10	24.89 (4.91)	2.44 [2.04, 2.84]	< 0.001		2.45 [2.07, 2.83]	< 0.001
20-29	21.90 (5.12)	-0.55 [-0.91, -0.18]	0.003		-0.54 [-0.91, -0.16]	0.005
30-39	21.93 (5.15)	-0.52 [-0.86, -0.18]	0.003		-0.64 [-1.00, -0.28]	< 0.001
40-49	21.53 (5.24)	-0.92 [-1.30, -0.54]	< 0.001		-1.00 [-1.39, -0.61]	< 0.001
50-59	21.75 (4.95)	-0.70 [-1.20, -0.20]	0.006		-0.84 [-1.34, -0.34]	0.001
60-69	22.01 (5.28)	-0.44 [-1.17, 0.29]	0.239		-0.61 [-1.33, 0.10]	0.093
70-79	22.16 (4.76)	-0.29 [-1.73, 1.16]	0.696		-0.04 [-1.42, 1.33]	0.952
80+	21.39 (5.29)	-1.06 [-3.37, 1.26]	0.371		-0.76 [-2.94, 1.42]	0.493
Sex				< 0.001		
Female	21.92 (5.12)	Ref.			Ref.	
Male	22.58 (5.26)	0.66 [0.44, 0.87]	< 0.001		0.48 [0.27, 0.70]	< 0.001
Nationality§				< 0.001		
Qatari	22.19 (4.95)	Ref.			Ref.	
Bangladeshi	21.75 (5.63)	-0.44 [-1.01, 0.13]	0.129		-0.14 [-0.71, 0.42]	0.617
Egyptian	22.88 (5.22)	0.68 [0.24, 1.13]	0.002		-0.08 [-0.50, 0.35]	0.717
Filipino	21.30 (5.46)	-0.89 [-1.35, -0.44]	< 0.001		-0.37 [-0.83, 0.08]	0.106
Indian	22.21 (5.27)	0.02 [-0.30, 0.34]	0.900		-0.29 [-0.64, 0.06]	0.110
Nepalese	22.50 (5.17)	0.31 [-0.24, 0.86]	0.265		-0.12 [-0.68,0.44]	0.677
Pakistani	22.50 (5.29)	0.30 [-0.19, 0.80]	0.227		0.07 [-0.41, 0.56]	0.766
Sri Lankan	23.21 (5.54)	1.02 [0.20, 1.83]	0.015		0.33 [-0.44, 1.10]	0.399
Sudanese	22.89 (4.85)	0.70 [-0.06, 1.46]	0.073		0.87 [0.16, 1.58]	0.017
Other nationalities¶	22.51 (5.25)	0.32 [0.02, 0.61]	0.034		0.13 [-0.15, 0.42]	0.357
Reason for RT-qPCR testing				< 0.001		
Survey	22.44 (5.08)	Ref.			Ref.	
Clinical suspicion	21.16 (4.99)	-1.28 [-1.61, -0.94]	< 0.001		-1.36 [-1.69, -1.04]	< 0.001
Contact tracing	22.25 (5.15)	-0.19 [-0.60, 0.23]	0.371		-0.37 [-0.76, 0.03]	0.073
Healthcare routine testing	22.71 (5.26)	0.27 [-0.49, 1.04]	0.483		-0.17 [-0.90, 0.56]	0.650
Port of entry	22.94 (5.18)	0.50 [0.16, 0.85]	0.004		0.93 [0.59, 1.27]	< 0.001
Pre-travel	24.14 (5.27)	1.70 [1.25, 2.15]	< 0.001		1.80 [1.37, 2.22]	< 0.001
Individual request	22.15 (5.41)	-0.29 [-0.79, 0.21]	0.262		0.36 [-0.14, 0.86]	0.158
Other	25.20 (5.18)	2.76 [1.63, 3.89]	< 0.001		-0.01 [-1.11, 1.09]	0.989
RT-qPCR test study-period month	,	, ,		< 0.001	, ,	
23 March-21 April, 2021	21.55 (4.55)	Ref.			Ref.	
22 April-21 May, 2021	21.54 (4.89)	-0.02 [-0.85, 0.81]	0.968		-0.17 [-0.96, 0.61]	0.666
22 May-20 June, 2021	22.64 (5.69)	1.09 [0.25, 1.93]	0.011		1.05 [0.24, 1.86]	0.011
21 June-20 July, 2021	20.34 (4.44)	-1.22 [-1.99, -0.44]	0.002		-1.14 [-1.90, -0.38]	0.003

21.7.110.4	21 00 (5 05)	0.05 5 0.00 1.053	0.240		0.10 5 0.50 0.043	0.500
21 July-19 August, 2021	21.90 (5.07)	0.35 [-0.38, 1.07]	0.348		0.13 [-0.58, 0.84]	0.722
20 August-18 September, 2021	23.47 (5.41)	1.92 [1.19, 2.65]	< 0.001		1.55 [0.84, 2.27]	< 0.001
19 September-18 October, 2021	23.04 (5.20)	1.49 [0.72, 2.26]	< 0.001		1.23 [0.47, 1.98]	0.001
19 October-06 November, 2021	21.76 (4.85)	0.21 [-0.59, 1.01]	0.606		0.26 [-0.53, 1.05]	0.524
Vaccination status				< 0.001		
Unvaccinated	22.56 (5.31)	Ref.			Ref.	
One dose	21.22 (5.24)	-1.34 [-2.02, -0.66]	< 0.001		0.35 [-0.29, 0.99]	0.281
Two doses						
<3 months before the RT-qPCR test	22.26 (4.98)	-0.30 [-0.72, 0.11]	0.151		0.87 [0.47, 1.27]	< 0.001
3-<6 months before the RT-qPCR test	21.98 (5.04)	-0.59 [-0.84, -0.33]	< 0.001		0.22 [-0.06, 0.50]	0.120
6-<9 months before the RT-qPCR test	21.62 (4.97)	-0.94 [-1.40, -0.49]	< 0.001		-0.23 [-0.72, 0.25]	0.347
≥9 months before the RT-qPCR test	18.81 (2.22)	-3.75 [-8.85, 1.35]	0.149		-3.15 [-7.87, 1.57]	0.191
Three doses						
≤1 month before the RT-qPCR test	17.72 (2.35)	-4.84 [-12.05, 2.36]	0.188		-3.46 [-10.16, 3.23]	0.311
>1 month before the RT-qPCR test	19.80 (2.97)	-2.77 [-7.87, 2.33]	0.287		-1.18 [-5.89, 3.53]	0.623
Prior SARS-CoV-2 infection				< 0.001		
Never	21.93 (5.11)	Ref.			Ref.	
<90 days before the study RT-qPCR test <sup>††</sup>	25.32 (4.95)	3.39 [3.05, 3.72]	< 0.001		4.03 [3.69, 4.38]	< 0.001
Prior infection#	24.00 (5.64)	2.07 [1.13, 3.02]	< 0.001		2.15 [1.26, 3.04]	< 0.001

Abbreviations: CI, confidence interval; Ct, cycle threshold; RT-qPCR, real-time reverse-transcription polymerase chain reaction; Ref., reference; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.

<sup>\*</sup>The two-tailed F-test of the univariable analysis.

<sup>†</sup>RT-qPCR Ct value was adjusted for age-group, sex, nationality, reason for RT-qPCR test, RT-qPCR test study-period month, vaccination status, and prior SARS-CoV-2 infection.

The 10-19 age group was chosen as a reference, and not the <10 age group, because of the different manifestations of this infection in small children.

<sup>§</sup>Nationalities were chosen to represent the most populous groups on Qatar.

These comprise 87 other nationalities in Qatar.

<sup>\*\*</sup>Inestimable quantity due to very small number of observations.

<sup>&</sup>lt;sup>††</sup>An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included as a separate category in the analysis and was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection.

<sup>‡</sup> Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study.

# **Supplementary Material**

#### **Table of contents**

#### 1. Laboratory methods and variant ascertainment

#### 1.1 Real-time reverse-transcription polymerase chain reaction testing

Nasopharyngeal and/or oropharyngeal swabs were collected for polymerase chain reaction (PCR) testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: 1) extracted on KingFisher Flex (Thermo Fisher Scientific, USA), MGISP-960 (MGI, China), or ExiPrep 96 Lite (Bioneer, South Korea) followed by testing with real-time reverse-transcription PCR (RT-qPCR) using TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher Scientific, USA); 2) tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or 3) loaded directly into a Roche cobas 6800 system and assayed with the cobas SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory, following standardized protocols. All PCR testing was performed with extensively used, investigated, and validated commercial platforms having essentially 100% sensitivity and specificity.

#### 1.2 Classification of infections by variant type

Surveillance for SARS-CoV-2 variants in Qatar is mainly based on viral genome sequencing and multiplex RT-qPCR variant screening(1) of random positive clinical samples,(2-7) complemented by deep sequencing of wastewater samples.(4, 8)

The accuracy of the RT-qPCR genotyping was verified against either Sanger sequencing of the receptor-binding domain (RBD) of SARS-CoV-2 surface glycoprotein (S) gene, or by viral

whole-genome sequencing on a Nanopore GridION sequencing device. From 236 random samples (27 Alpha-like, 186 Beta-like, and 23 "other" variants), PCR genotyping results for Alpha-like, Beta-like, and 'other' variants were in 88.8% (23 out of 27), 99.5% (185 out of 186), and 100% (23 out of 23) agreement with the SARS-CoV-2 lineages assigned by sequencing. Within the "other" variant category, Sanger sequencing and/or Illumina sequencing of the RBD of SARS-CoV-2 spike gene on 728 random samples confirmed that 701 (96.3%) were Delta cases and 17 (2.3%) were other variant cases, with 10 (1.4%) samples failing lineage assignment. Accordingly, a Delta case was proxied as any "other" case identified through the RT-qPCR based variant screening.

All the variant RT-qPCR screening was conducted at the Sidra Medicine Laboratory following standardized protocols.

## 2. Supplementary tables

## Supplementary table 1. STROBE checklist for cross-sectional studies.

	Item No	Recommendations	Main text page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Methods ('Study population, data sources, and study design', paragraph 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Methods ('Study population, data sources, and study design')
Methods			
Study design	4	Present key elements of study design early in the paper	Methods ('Study population, data sources, and study design')
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods ('Study population, data sources, and study design') and Section 1 ('Classification of infections by variant type') of Supplementary Material
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Methods ('Study population, data sources, and study design') & Figure 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods ('Study population, data sources, and study design' & 'Statistical analysis') & Sections 1 ('Classification of infections by variant type') of Supplementary Material
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Methods ('Study population, data sources, and study design'), Table 1, & Section 1 of Supplementary Material
Bias	9	Describe any efforts to address potential sources of bias	Methods ('Study population, data sources, and study design' & 'Statistical analysis')
Study size	10	Explain how the study size was arrived at	Methods ('Study population, data sources, and study design') & Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods ('Study population, data sources, and study design' & 'Statistical analysis'), & Tables 1-5
		(a) Describe all statistical methods, including those used to control for confounding	Methods ('Statistical analysis')
		(b) Describe any methods used to examine subgroups and interactions	Methods ('Study population, data sources, and study design' & 'Statistical analysis'), & Tables 3-5
Statistical methods	12	(c) Explain how missing data were addressed	Methods ('Study population, data sources, and study design') & Figure 1
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram (a) Give characteristics of study participants (eg	
Descriptive data	14	demographic, clinical, social) and information on exposures and potential confounders	Table 1

		(b) Indicate number of participants with missing data for each variable of interest	Methods ('Study population, data sources, and study design') & Figure 1
Outcome data	15	Report numbers of outcome events or summary measures	Results & Table 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results & Table 2
		(b) Report category boundaries when continuous variables were categorized	Tables 1-2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results & Tables 3-5
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion, paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, paragraph 5-6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, paragraph 1
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, paragraph 6
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Acknowledgements

Abbreviations: NA: not applicable.

#### References

- 1. Vogels C, Fauver J, Grubaugh N. Multiplexed Rt-Qpcr to Screen for Sars-Cov-2 B.1.1.7, B.1.351, and P.1 Variants of Concern V.3. Dx.Doi.Org/10.17504/Protocols.lo.Br9vm966 (2021) [June 6, 2021]. Available from: <a href="https://www.protocols.io/view/multiplexed-rt-qpcr-to-screen-for-sars-cov-2-b-1-1-br9vm966">https://www.protocols.io/view/multiplexed-rt-qpcr-to-screen-for-sars-cov-2-b-1-1-br9vm966</a>.
- 2. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid Vaccination. Effectiveness of the Bnt162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* (2021) 385(2):187-9. Epub 2021/05/06. doi: 10.1056/NEJMc2104974.
- 3. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. Mrna-1273 Covid-19 Vaccine Effectiveness against the B.1.1.7 and B.1.351 Variants and Severe Covid-19 Disease in Qatar. *Nat Med* (2021) 27(9):1614-21. Epub 2021/07/11. doi: 10.1038/s41591-021-01446-y.
- 4. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar Viral Genome Sequencing Data. Data on Randomly Collected Samples. <a href="https://www.Gisaid.org/Phylodynamics/Global/Nextstrain/">https://www.Gisaid.org/Phylodynamics/Global/Nextstrain/</a> (2021). Available from: <a href="https://www.gisaid.org/phylodynamics/global/nextstrain/">https://www.gisaid.org/phylodynamics/global/nextstrain/</a>.
- 5. Benslimane FM, Al Khatib HA, Al-Jamal O, Albatesh D, Boughattas S, Ahmed AA, et al. One Year of Sars-Cov-2: Genomic Characterization of Covid-19 Outbreak in Qatar. *Front Cell Infect Microbiol* (2021) 11:768883. Epub 2021/12/07. doi: 10.3389/fcimb.2021.768883.
- 6. Hasan MR, Kalikiri MKR, Mirza F, Sundararaju S, Sharma A, Xaba T, et al. Real-Time Sars-Cov-2 Genotyping by High-Throughput Multiplex Pcr Reveals the Epidemiology of the Variants of Concern in Qatar. *Int J Infect Dis* (2021) 112:52-4. Epub 2021/09/16. doi: 10.1016/j.ijid.2021.09.006.
- 7. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of Bnt162b2 Vaccine Protection against Sars-Cov-2 Infection in Qatar. *N Engl J Med* (2021) 385(24):e83. Epub 2021/10/07. doi: 10.1056/NEJMoa2114114.
- 8. Saththasivam J, El-Malah SS, Gomez TA, Jabbar KA, Remanan R, Krishnankutty AK, et al. Covid-19 (Sars-Cov-2) Outbreak Monitoring Using Wastewater-Based Epidemiology in Qatar. *Sci Total Environ* (2021) 774:145608. Epub 2021/02/20. doi: 10.1016/j.scitotenv.2021.145608.